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Deletion of the Androgen Receptor in Adipose Tissue in
Male Mice Elevates Retinol Binding Protein 4 and
Reveals Independent Effects on Visceral Fat Mass and on
Glucose Homeostasis
Kerry J. McInnes,1 Lee B. Smith,2 Nicole I. Hunger,1 Philippa T.K. Saunders,2 Ruth Andrew,1
and Brian R. Walker1
Testosterone deﬁciency is epidemic in obese ageing males with
type 2 diabetes, but the direction of causality remains unclear.
Testosterone-deﬁcient males and global androgen receptor (AR)
knockout mice are insulin resistant with increased fat, but it is
unclear whether AR signaling in adipose tissue mediates body fat
redistribution and alters glucose homoeostasis. To investigate
this, mice with selective knockdown of AR in adipocytes (fARKO)
were generated. Male fARKO mice on normal diet had reduced
perigonadal fat but were hyperinsulinemic and by age 12 months,
were insulin deﬁcient in the absence of obesity. On high-fat diet,
fARKO mice had impaired compensatory insulin secretion and
hyperglycemia, with increased susceptibility to visceral obesity.
Adipokine screening in fARKO mice revealed a selective in-
crease in plasma and intra-adipose retinol binding protein
4 (RBP4) that preceded obesity. AR activation in murine 3T3
adipocytes downregulated RBP4 mRNA. We conclude that AR
signaling in adipocytes not only protects against high-fat diet–
induced visceral obesity but also regulates insulin action and
glucose homeostasis, independently of adiposity. Androgen de-
ﬁciency in adipocytes in mice resembles human type 2 diabetes,
with early insulin resistance and evolving insulin deﬁciency.
Diabetes 61:1072–1081, 2012
Testosterone deﬁciency is being diagnosed withincreasing frequency in older men with obesityand type 2 diabetes. Although obesity may bea reversible risk factor for low testosterone lev-
els, an increasing body of evidence suggests that low tes-
tosterone promotes insulin resistance and increases the
risk of type 2 diabetes (1–3). Furthermore, testosterone
replacement therapy improves glycemic control in hypo-
gonadal men with type 2 diabetes (4). However, the amount
and distribution of body fat is also strongly inﬂuenced by
sex steroids, and low plasma testosterone levels are asso-
ciated with visceral obesity (5,6), an independent risk factor
for insulin resistance and type 2 diabetes. It is unclear
whether testosterone deﬁciency directly promotes insulin
resistance and hyperglycemia over and above its association
with visceral obesity.
Testosterone exerts its effects by binding to the andro-
gen receptor (AR), which mediates most of its biological
functions through transcriptional activation of downstream
genes. ARs are present in adipose tissue, at a higher level in
visceral fat than other adipose depots (7), and AR activation
affects adipocyte differentiation (8) and lipid metabolism
(9). However, although global deletion of AR in mice results
in late-onset obesity (10) accompanied by adipocyte hy-
pertrophy (11), adipocyte-speciﬁc AR knockdown (crossing
aP2-cre with ﬂoxed AR mice) had no reported effect on
body weight, adiposity, or fasting plasma glucose and in-
sulin concentrations, despite reducing plasma lipids (12).
This contrasts with increased susceptibility to obesity, he-
patic steatosis, hyperinsulinemia, and hyperglycemia in
mice with liver-speciﬁc AR deletion (13). However, since
the adipose-speciﬁc AR knockdown mice were studied only
by fasting blood samples at age 20 weeks and without high-
fat (HF) diet, and given that androgen deﬁciency predisposes
to age-associated deterioration in glucose homoeostasis, we
speculated that a more subtle phenotype might result from
androgen deﬁciency in adipose tissue and that effects on fat
redistribution/accumulation may be separable from those on
insulin sensitivity and glucose homoeostasis.
RESEARCH DESIGN AND METHODS
Breeding and maintenance of transgenic mice. Male mice in which AR has
been selectively knocked down in adipose tissue were generated using
Cre/loxP technology. Male mice heterozygous for Cre recombinase under the
control of the fatty acid binding protein aP2 promoter (The Jackson Labora-
tories) or the adiponectin promoter (14), both on a C57Bl/6 congenic back-
ground, were mated to female mice homozygous for a ﬂoxed AR on the
X chromosome, also on a C57Bl/6 background (15). The aP2-Cre-positive, ARﬂox-
positive male offspring from these matings are termed fARKO, and the
adiponectin-Cre-positive, ARﬂox-positive male offspring are termed adipoQ-
fARKO. The Cre-negative, ARﬂox-positive littermates were used as controls
(termed control). Sex and genotype ratios were all produced at the expected
Mendelian ratios. All mice were bred under standard conditions of care and
used under licensed approval from the U.K. Home Ofﬁce. Animals were fed
standard chow (product 801151; Special Diet Services, Essex, U.K.) ad libi-
tum unless stated otherwise. Genotyping was performed using genomic DNA
isolated from the ear for the presence of Cre by PCR (http://jaxmice.jax.org/
protocolsdb/f?p=116:2:3835741438358292::NO:2:P2_MASTER_PROTOCOL_ID,
P2_JRS_CODE:288%2C005069).
Females homozygous for ARﬂox were identiﬁed using primers for AR exon 2.
All fARKO male offspring were genotyped for the presence of Cre using the
primers detailed above. The assessment of AR recombination was performed
by RT-PCR from cDNA from isolated tissues from fARKO and adipoQ-fARKO
mice and control littermates using a previously described PCR strategy (16) in
which a 765–base pair ampliﬁed product indicated mice with a ﬂoxed allele of
AR and a 613–base pair product indicated mice with an excised exon 2 allele
of AR.
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Experimental design.Male mice maintained on standard chow diet (n = 8–10
per group) were killed at various postnatal ages (3, 6, and 12 months) by in-
halation of CO2 and subsequent cervical dislocation. Immediately after killing,
blood was collected from mice by cardiac puncture. Plasma was separated
and stored at 220°C until assayed. Body weight was measured and liver and
adipose tissue beds (perigonadal, subcutaneous, mesenteric, omental, and inter-
scapular brown) were removed and weighed. Tissues were either snap frozen for
subsequent RNA and protein analysis or ﬁxed in Bouin ﬁxative for 6 h. A further
cohort of male fARKO and control mice (n = 8–10 per group) were maintained on
standard chow, and intraperitoneal glucose tolerance tests (GTTs) were per-
formed after a 6-h fast at age 3, 6, 9, and 12 months as previously described (17).
For insulin signaling experiments, a further cohort of 3-month-old male mice
(n = 6 per group) were fasted for 6 h, injected with insulin (10 mU/g body wt i.p.),
and killed 10 min later. Perigonadal and subcutaneous adipose tissue was dis-
sected and snap frozen in liquid N2.
To address responses to a diet previously optimized for inducing weight gain
and insulin resistance (18), groups of male fARKO and control mice (n = 8–10
per group) were fed an HF diet (product D12331, 58% calories as fat with
sucrose; Research Diets, New Brunswick, NJ) for a period of 24 weeks. After
6, 12, and 24 weeks of HF-diet feeding, body weight was measured and in-
traperitoneal GTTs were performed as described above. Mice were killed after
24 weeks of HF diet. Plasma was prepared as described above, and liver and
adipose tissue beds were dissected, weighed, and snap frozen for subsequent
analysis.
Biochemical assays. Testosterone was measured using a previously published
radioimmunoassay (19). All samples from each mouse were run in a single
assay, and the within-assay coefﬁcients of variation were all ,10%. Glucose
was determined by the hexokinase method (Sigma-Aldrich, Dorset, U.K.) and
plasma insulin and leptin by ELISA (Crystal Chem, Inc., Downers Grove, IL).
On a subset of animals, triglycerides and total cholesterol were measured in
fasting plasma by colorimetric enzyme assay (Thermo Electron, Melbourne,
Australia). Nonesteriﬁed fatty acid (NEFA) levels were analyzed using
a NEFA-kit (Wako Chemicals GmBH).
Hepatic triglyceride content. Liver was homogenized in 4–10 vol propan-2-ol
(VWR International Ltd., Lutterworth, U.K.) for 23 20 s and cleared of debris by
centrifugation (.10,000g for 10 min), and the supernatant was assayed using
a triglyceride kit (Thermo Electron).
Plasma retinol binding protein 4 measurement. Plasma was diluted
10 times in sample buffer (0.125mol/L Tris pH 6.8, 4%SDS, 20% glycerol, 0.2mg/mL
bromophenol blue) containing dithiothreitol (200 mmol/L), and proteins
were separated by 15% SDS-PAGE and transferred to nitrocellulose mem-
branes. Mouse retinol binding protein 4 (RBP4) was detected using anti-
human RBP4 polyclonal antisera (DAKO) (20). The anti-human antibody also
recognizes mouse RBP4 but with lower afﬁnity.
FIG. 1. Generation of male fat-speciﬁc AR knockouts. A: Deletion of AR in the fat was determined using RT-PCR spanning exon 2. Only the larger
765bp ﬂoxed band was seen in adrenal, kidney, skeletal muscle (sk.musc), and liver. Both bands were identiﬁed in subcutaneous (SC) and per-
igonadal (PG) fat and in brown adipose tissue (BAT) showing deletion of the AR in a proportion of cells in white and brown adipose tissue.
B: Quantitative real-time PCR using AR exon 2-speciﬁc primers conﬁrmed loss of AR exon 2 in subcutaneous and gonadal fat, but not in the liver of
fARKO mice. C: Quantitative real-time PCR using AR exon 2-speciﬁc primers conﬁrmed loss of AR exon 2 in the adipocyte fraction only of gonadal
fat. D: Deletion of AR in the fat of adipoQ-fARKO mice was determined using RT-PCR spanning exon 2. Only the larger 765bp ﬂoxed band was seen
in adrenal, kidney, and liver. Both bands were identiﬁed in SC fat, PG fat, mesenteric (mes.) fat, and in BAT showing deletion of AR in a proportion
of cells in white and brown adipose tissue. E: Deletion of AR exon 2 was determined in the brain using RT-PCR. AR exon 2 was deleted in the brain
of fARKO mice generated with aP2-Cre (aP2) but not in mice using adiponectin-Cre (adipoQ). Data are mean6 SEM (n = 8–10). **P< 0.01 control
vs. fARKO; ***P < 0.001 control vs. fARKO. bp, base pair; con, control; ko, knockout.
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White adipose tissue histology. Bouin-ﬁxed perigonadal fat pads were
processed and embedded in parafﬁn wax, and 5-mm sections were stained with
hematoxylin-eosin. Images were acquired using a Zeiss microscope (Welwyn
Garden City, Hertfordshire, U.K.) equipped with a Kodak DCS330 camera
(Eastman Kodak, Rochester, NY).
Adipocyte size. Adipocyte size was determined by measuring adipocytes
from 20 randomly selected areas in sections from perigonadal and sub-
cutaneous fat depots of 3-month-old fARKO and control mice fed a normal
chow diet using a Zeiss KS300 image analyzer. The marker was blind to
genotype.
Adipocyte and stromal vascular fraction isolation. The adipocyte and
stromal vascular fraction (SVF) were isolated from perigonadal fat pads as
described previously (21). In brief, fat pads were chopped with ﬁne scissors
and digested with 2 mg/mL collagenase type 1 (Worthington Biochemical,
Reading, U.K.) in Hanks’ buffered saline solution (Life Technologies, Inc.,
Paisley, Scotland) for 1 h at 37°C, then washed twice with Hanks’ buffered
saline solution. Digested material was separated by centrifugation at 1,000g for
8 min (Heraeus; DJB Labcare, Buckinghamshire, U.K.). Freshly isolated SVF
fraction and cell supernatant (adipocyte fraction) were then added to TRIzol
(Invitrogen, Paisley, Scotland) for RNA extraction.
Quantitative analysis of mRNA. Total RNA was extracted from snap-frozen
tissue samples or adipocyte fractions using TRIzol reagent (Invitrogen) and the
RNeasy Mini system (QIAGEN, Crawley, U.K.). RNA was reverse transcribed
using the Quantitect reverse-transcription kit (QIAGEN). cDNA (equivalent to
250 ng total RNA) was incubated in triplicate with gene-speciﬁc primers
(Invitrogen) and ﬂuorescent probes (using the Universal Probe Library system
[Roche Applied Science, Burgess Hill, U.K.]) in 13 Roche LightCycler 480
Probes mastermix (Supplementary Table 1). PCR cycling and detection of
ﬂuorescent signal was carried out using a Roche LightCycler 480. A standard
curve was constructed for each primer-probe set using a serial dilution of
cDNA pooled from all samples. Results were corrected for the expression of
b-actin, which did not change between groups.
Western blotting to investigate signal transduction. Lysates were pre-
pared from perigonadal and subcutaneous fat by extraction in ice-cold buffer as
described above. Adipose tissue lysates (500 mg) were subjected to immuno-
precipitation with anti-insulin receptor substrate (IRS)1 (4 mg) antibody
(Millipore, Watford, U.K.). Immune complexes were collected on protein
A-Sepharose beads (Pierce), washed three times with lysis buffer and twice
with 13 PBS containing 2 mmol/L Na3VO4, resuspended in SDS-PAGE sample
buffer, and heated for 10 min at 95°C. Western blotting was performed using
phosphospeciﬁc antibodies to IRS-1 Tyr-612 (Invitrogen). Proteins were vi-
sualized with an Alexa Fluor 800 goat anti-rabbit secondary antibody (LI-COR
Biosciences, Lincoln, NE), and band intensities were quantiﬁed using the
Odyssey infrared imaging system (LI-COR Biosciences).
Adipocyte cell culture. 3T3-L1 cells were seeded at 3 3 105/mL in six-well
plates and maintained at no higher than 70% conﬂuence in Dulbecco’s modiﬁed
Eagle’s medium supplemented with 10% FCS, 100 IU/mL penicillin, 100 mg/mL
streptomycin, and 200 mmol/L L-glutamine (all from Lonza Biologics,
Tewkesbury, U.K.). Differentiation of cells into mature adipocytes was
induced as previously described (22). Medium was replaced with serum- and
phenol red–free Dulbecco’s modiﬁed Eagle’s medium for 24 h before treat-
ment with dihydrotestosterone (DHT; Sigma-Aldrich) at 100 nmol/L for 24 h.
After treatment with DHT, cells were washed with ice-cold PBS and lysed in
ice-cold buffer (5 mmol/L HEPES, 137 mmol/L NaCl, 1 mmol/L MgCl2, 1 mmol/L
CaCl2, 10 mmol/L NaF, 2 mmol/L EDTA, 10 mmol/L Na pyrophosphate,
2 mmol/L Na3VO4, 1% Nonidet P-40, and 10% glycerol) containing protease
inhibitors (Complete Mini; Roche Diagnostics Ltd.) as previously described
(22). Cell lysate (50 mg) was subjected to SDS-PAGE, and RBP4 levels were
assayed by Western blotting with an RBP4 antibody as described above.
Proteins were visualized and quantiﬁed as described above.
FIG. 2. Body and fat pad weights on normal chow diet. A: Body weight of male fARKO and control mice on standard chow and aged 3, 6, and 12
months. B: Relative fat pad masses of male fARKO and control mice on standard chow and aged 3 and 12 months. Data are mean 6 SEM (n = 8–10).
*P < 0.05, **P < 0.01 control vs. fARKO. C: There was no difference between fARKO and control mice on standard chow and aged 3 months in the
morphology or size of white adipose tissue from the perigonadal or subcutaneous fat pad. Data are representative images from the two experi-
mental groups (n = 3). (A high-quality color representation of this ﬁgure is available in the online issue.)
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Statistical analysis. Data are expressed as means 6 SE. Data were analyzed
using GraphPad Prism (version 4; GraphPad Software Inc., San Diego, CA)
using two-tailed unpaired Student t tests.
RESULTS
Generation of mice with fat-speciﬁc deletion of ARs.
In male fARKO mice, AR expression was preserved in ad-
renal, kidney, liver, and skeletal muscle (Fig. 1A). Brown
and white adipose tissue from fARKO mice expressed both
the ﬂoxed and knockout mRNA band, demonstrating that
AR had been deleted from a proportion of cells within the
adipose tissue (Fig. 1A). AR mRNA was reduced by 70–80%
in whole adipose tissue (Fig. 1B) and by 85–95% in isolated
adipocytes of fARKO mice (Fig. 1C). The remaining AR ex-
pression could be derived from vascular endothelial cells or
stromal cells since AR exon 2 expression was preserved
in the SVF (Fig. 1C). It is important that circulating
testosterone levels were not different between control and
fARKO littermates (3 months: 2.0 6 1.34 vs. 2.3 6 1.7 ng/mL;
12 months: 2.36 6 0.78 vs. 2.01 6 0.97 ng/mL, respectively).
Since AP2-Cre is known to be expressed also in the
central nervous system (CNS), and fARKO mice showed
AR deletion in CNS as well as adipose tissue (Fig. 1E),
adipoQ-fARKO mice were also generated. AdipoQ-fARKO
mice exhibit AR deletion in all adipose depots (Fig. 1D)
but not in CNS (Fig. 1E).
fARKO mice have impaired insulin sensitivity and
age-related glucose intolerance, independently of
obesity. Age-dependent differences in body composition
and glucose/insulin homoeostasis in male mice on normal
chow diet are shown in Figs. 2 and 3. At age 3 months,
fARKO mice had gained less weight than controls (Fig. 2A),
with perigonadal fat reduced in weight (0.27 6 0.017 vs.
0.36 6 0.02 g, P , 0.01) and proportion (Fig. 2B), while
FIG. 3. Glucose homeostasis on normal chow diet. Plasma glucose (A and C) and plasma insulin (B and D) during intraperitoneal GTT of male
control and fARKO mice on standard chow at 3, 6, 9, and 12 months of age. Mice were fasted for 6 h before testing. Solid line denotes control mice;
broken line denotes fARKOmice. Area under the curve (AUC) for all groups shown for glucose (C) and insulin (D). Data are mean6 SEM (n = 8–10)
for individual time points. *P < 0.05, **P < 0.01, ***P < 0.001 control vs. fARKO.
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only interscapular brown adipose tissue was proportion-
ately increased in 3-month-old fARKO males (5.0 6 0.3 vs.
4.1 6 0.3 mg/g, P = 0.02). White adipose tissue morphology
and adipocyte size in the perigonadal and subcutaneous
depots were unaltered (Fig. 2C). Body composition was no
longer signiﬁcantly different by age 6 months and remained
similar at age 12 months (Fig. 2A and B).
Despite their lack of obesity at age 3 months, fARKO
mice were euglycemic (Fig. 3A and C) but hyperinsulinemic
(Fig. 3B and D) both in the fasted state and during GTT. At
age 3 months, fARKO mice had normal liver triglycerides
but elevated plasma triglyceride levels (Table 1). Although
plasma NEFA levels and the suppression rate of NEFA in
response to a glucose bolus were not signiﬁcantly different
between the groups (Table 1), transcript levels for hormone-
sensitive lipase and lipoprotein lipase were elevated in
perigonadal and subcutaneous adipose tissue, and tran-
script levels for adipose triglyceride lipase and fatty acid
synthase were elevated speciﬁcally in subcutaneous adi-
pose tissue (Fig. 4A). Adipose insulin resistance was
conﬁrmed in fARKO mice at age 3 months, since in peri-
gonadal and subcutaneous adipose tissue, total IRS-1
levels were comparable to those seen in wild-type mice,
TABLE 1
Metabolic parameters for fARKO mice
Control fARKO
Liver triglycerides (mmol/g) 11.3 6 0.4 11.8 6 0.4
Plasma triglycerides (mmol/L) 0.6 6 0.03 0.95 6 0.09*
Plasma NEFA (mmol/L) 0.77 6 0.03 0.84 6 0.06
NEFA suppression (%) 19.2 6 3.4 15.2 6 3.3
Plasma total cholesterol (mmol/L) 1.88 6 0.2 1.65 6 0.1
Data are mean 6 SEM (n = 8–10). Liver and plasma triglycerides,
NEFAs, and total cholesterol levels were analyzed in 3-month-old
fARKO and control littermates maintained on standard chow diet.
Plasma triglycerides, NEFAs, and total cholesterol were measured in
fasted (6 h) animals. Liver triglycerides were measured in fed animals.
NEFA suppression was calculated as the percent suppression in plasma
NEFA levels measured between 0 and 15 min after a glucose bolus was
administered to 6-h–fasted animals. *P , 0.05 vs. control.
FIG. 4. Adipose transcript levels and adipose insulin resistance in fARKO mice. A: mRNA levels were measured for adipose triglyceride lipase
(ATGL), fatty acid synthase (FAS), hormone-sensitive lipase (HSL), and lipoprotein lipase (LPL) by quantitative PCR in perigonadal and sub-
cutaneous adipose tissue of 3-month-old fARKO and control mice on standard chow. B and C: Representative Western blots of IRS-1 pY612
phosphorylation in perigonadal and subcutaneous adipose tissue lysates. Data are mean 6 SEM; (n = 8–10). *P < 0.05 control vs. fARKO, **P <
0.01 control vs. fARKO, ***P < 0.001 control vs. fARKO. con, control; ko, knockout; IP, immunoprecipitation; A.U., arbitrary unit.
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but insulin-stimulated IRS-1 Tyr phosphorylation was re-
duced (Fig. 4B and C).
Between age 3 and 12 months, fARKO mice were un-
able to sustain the normal increase in insulin secretory
capacity, and they developed hyperglycemia. As a result,
at age 6 months, when fARKO mice were in transition
between hyperinsulinemia and insulin deﬁciency, there
were no statistically signiﬁcant differences in glucose
and insulin levels either fasted or during a GTT (Fig. 3A
and B).
fARKO mice are more susceptible to HF diet–induced
visceral obesity and glucose intolerance. With HF
feeding, AR expression in adipose tissue was reduced to
a similar level as seen with normal diet; no evidence of
extra-adipose Cre expression was observed, and circulat-
ing testosterone levels were unaffected by diet or AR
knockdown (2.9 6 0.5 vs. 4.4 6 3.2 ng/mL in fARKO and
controls, respectively, after 24 weeks). On HF diet, male
fARKO mice gained equal weight compared with controls
(Fig. 5A) but, after 24 weeks, had more visceral fat, with
increased omental and mesenteric fat pad weights (Fig. 5B).
Control animals on HF diet were hyperglycemic after
6 weeks but showed a progressive increase in insulin se-
cretion such that glucose tolerance, if anything, improved
by 24 weeks (Fig. 6). In contrast, fARKO mice had a poorer
insulin secretory response and became signiﬁcantly more
hyperglycemic than control mice at 24 weeks (Fig. 6).
There was no increase in triglyceride accumulation in the
livers (0.05 6 0.01 vs. 0.05 6 0.007 mmol/L) or plasma
(1.03 6 0.07 vs. 0.93 6 0.08 mmol/L) of fARKO mice
compared with controls, and plasma NEFA levels were
not different between groups after 24 weeks on HF diet
(0.61 6 0.04 vs. 0.73 6 0.09 mmol/L in fARKO and controls,
respectively).
Impaired insulin sensitivity in fARKO mice is as-
sociated with an altered adipokine proﬁle and AR-
dependent increased RBP4 levels. To identify adipose-
derived factors that might mediate insulin resistance in the
absence of obesity, we focused on samples from 3-month-old
male mice on normal chow diet. Contrary to a previous
report of similar 20-week-old animals (12), neither leptin
transcript levels in adipose depots (Fig. 7A) nor fasted or
fed plasma leptin levels differed between fARKO and control
mice (Fig. 7B). Adiponectin transcript levels were elevated,
rather than downregulated, in perigonadal and subcutaneous
fat of fARKO mice (Fig. 7A). Resistin mRNA was modestly
increased selectively in subcutaneous fat in fARKO mice
(Fig. 7A). However, RBP4 mRNA in both perigonadal and
subcutaneous adipose (Fig. 7A) and protein levels in plasma
(Fig. 7C) were increased in fARKO mice with no difference
in hepatic RBP4 transcript levels (Fig. 7D). This adipose-
speciﬁc AR-mediated regulation of RBP4 was further con-
ﬁrmed in a second fat-speciﬁc ARKO model driven by the
adiponectin promoter (Fig. 7E).
In differentiated 3T3-L1 adipocytes, the nonaromatizable
androgen DHT reduced RBP4 mRNA levels (Fig. 7F).
DISCUSSION
We have demonstrated an important role for AR in adipose
tissue in regulating glucose/insulin homeostasis in mice.
Male fARKO mice exhibit a pattern of age-dependent met-
abolic dysregulation typical of the evolution of human type
2 diabetes, with early insulin resistance/hyperinsulinemia/
hypertriglyceridemia followed by later insulin deﬁciency
on normal chow and accelerated insulin deﬁciency and
hyperglycemia on HF diet. This dynamic evolution likely
explains the absence of a detectable metabolic phenotype
in previous studies of a similar strain of mice at age 5
months (12). Furthermore, although fARKO mice are
more susceptible to visceral obesity on HF diet, obesity is
not a prerequisite for early insulin resistance or later in-
sulin deﬁciency in these mice; indeed, at age 3 months,
insulin resistant fARKO mice are smaller with less body
fat than controls. Unlike liver-speciﬁc AR-deﬁcient mice
(13), there was no evidence of hepatic steatosis and
normal NEFA levels in fARKO mice, making “spillover” of
fatty acids into extra-adipose organs unlikely as a mech-
anism underlying their insulin resistance. However, con-
sistent with adipose tissue–dependent insulin resistance
without obesity, fARKO mice showed an unusual pattern
of altered adipokines, with paradoxically elevated adi-
ponectin, normal leptin, and elevated RBP4. The inferred
FIG. 5. Effect of HF diet on body composition. A: Weight gain after 6,
12, and 24 weeks of HF diet. B: Relative fat pad masses of male
fARKO and control mice fed an HF diet for 24 weeks. Data are
mean 6 SEM (n = 8–10). *P < 0.05, **P < 0.01 control vs. fARKO.
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downregulation of RBP4 by androgens was conﬁrmed in
murine adipocytes in culture.
Testosterone is an important regulator of body compo-
sition in males, and there is an inverse relationship be-
tween total serum testosterone and the amount of visceral
adipose tissue. This is observed in age-related hypogonadism
(23), inherited testosterone deﬁciency (24), and androgen-
deprivation therapy during treatment of prostate cancer
(25). Several lines of evidence demonstrate that the anti-
obesity actions of testosterone are mediated via AR. First,
men with genetic androgen resistance linked to CAG
repeats in the AR gene, which decreases AR-mediated gene
transcription, have an excess of visceral fat (26). Second,
male mice lacking AR in all tissues develop late-onset vis-
ceral obesity (10,27). Consistent with previous reports in
3-month-old global ARKO mice (27), fARKO mice weighed
less than their control littermates. Over the next few weeks,
their body weight caught up with that of the control mice; yet
in marked contrast with mice with whole-body AR deﬁciency
(10,11), fARKO mice did not spontaneously become obese.
This suggests that AR activity in extra-adipose tissues, such
as skeletal muscle, contributes to the effect of testosterone
on body composition. Of interest, since the Ap2-cre “leaks” in
CNS and fARKO mice have AR deletion in brain, the current
experiment suggests that the spontaneous obesity in global
ARKO mice is not attributed to altered androgen action in
brain. In keeping with the obesity of androgen resistance
being dependent on an interaction between AR signaling in
adipose tissue and dietary caloric intake, fARKO mice did
accumulate more visceral fat on highly palatable HF feeding.
However, detailed metabolic balance studies have yet to be
reported to establish the consequences of global or tissue-
speciﬁc androgen resistance on food intake.
Despite the absence of an increase in body weight and
adiposity, fARKO mice on normal diet exhibit impaired
insulin sensitivity, as evidenced by hyperinsulinemia both
FIG. 6. Effect of HF diet on glucose homeostasis. Plasma glucose (A and C) and plasma insulin (B and D) during intraperitoneal GTT of male
control and fARKO mice on HF diet for 6, 12, and 24 weeks. Mice were fasted for 6 h before testing. Solid line denotes control mice; broken line
denotes fARKO mice. Area under the curve (AUC) for all groups shown for glucose (C) and insulin (D). Data are mean 6 SEM (n = 8–10) for
individual time points. *P < 0.05, **P < 0.01 control vs. fARKO.
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FIG. 7. Increased RBP4 expression in fARKO mice. A: Adipokine mRNA expression in perigonadal and subcutaneous fat of 3-month-old fARKO and
control mice on standard chow as measured by quantitative PCR. B: Circulating fasting (16 h) and fed leptin levels as measured by enzyme-linked
immunosorbent assay of 3-month-old control and fARKO plasma. C: Circulating RBP4 levels in plasma as measured by Western blot in 3-month-old
male control and fARKO mice maintained on standard chow. Con, control; KO, knockout; A.U., arbitrary unit. D: Hepatic RBP4 mRNA levels as
measured by quantitative PCR in 3-month-old male control and fARKO mice maintained on standard chow. E: Adipose mRNA levels for AR and
RBP4 as measured by quantitative PCR in perigonadal adipose tissue of 3-month-old male control and fARKO mice generated with aP2-cre and
adiponectin-cre maintained on standard chow. Data are mean 6 SEM (n = 8–10). *P < 0.05, **P < 0.01, ***P < 0.001 control vs. KO. F: Repre-
sentative Western blot of RBP4 in 3T3-L1 adipocytes incubated with vehicle (0.01% ethanol) or DHT (100 nmol/L) for 24 h. Data are mean 6 SEM.
**P < 0.01 vs. vehicle treatment.
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fasting and during GTTs. This is of similar magnitude to the
insulin resistance that occurs at age 20 weeks in nonobese
whole-body AR2/y mice (27), suggesting that loss of AR in
adipose tissue may directly reduce insulin sensitivity with-
out ﬁrst increasing body weight or adiposity. However,
these ﬁndings are in contrast to a previously published
adipose-speciﬁc ARKO model in which there was no alter-
ation in fasting plasma glucose or insulin at age 20 weeks
(12). By assessing glucose tolerance across the life span and
with or without the challenge of an HF diet, we demon-
strated that insulin resistance is apparent in fARKO mice
from age 12 weeks and that insulin deﬁciency develops with
ageing and HF diet. Furthermore, with an HF diet, the ad-
verse metabolic phenotype becomes more severe and
fARKO mice develop visceral obesity and hyperglycemia. We
therefore sought adipose-derived factors that are likely to
explain both insulin resistance and subsequent deﬁciency.
Among the major models currently proposed for the role
of adipose tissue in the pathogenesis of insulin resistance,
one proposes that an increase in the release of NEFA from
adipose tissue causes insulin resistance, whereas another
implicates differences in adipokine levels (28). Fasting
NEFA levels were not different between fARKO mice and
controls, and NEFA suppression in response to glucose
administration was similar in both groups. On the other
hand, the expression of several adipokines was altered in
fARKO mice. The antidiabetic properties of adiponectin
have attracted considerable attention. A number of studies
in humans, nonhuman primates, and rodents show that
hypoadiponectinemia is a common feature of obesity and
insulin resistance (29–31). In contrast, fARKO mice have
elevated adiponectin levels. The association between
hyperadiponectinemia and insulin resistance has pre-
viously been reported in adipocyte-speciﬁc Insr knock-
out (FIRKO) mice (32) and their human counterparts
(33) and is consistent with data from global AR-deﬁcient
mice (11) and hypogonadal men (34). We infer that testos-
terone acts via AR in adipose tissue to suppress adiponectin
levels in males, but reduced adiponectin is not responsible
for insulin resistance in fARKO mice.
Elevated RBP4 levels recently have been reported to
be associated with insulin resistance in several insulin-
resistant mouse models and in patients with type 2 diabe-
tes (20). In humans, there is a strong association between
elevated serum RBP4 concentrations and components of
metabolic syndrome, including increased BMI and waist
circumference (35). RBP4 expression is higher in visceral
versus subcutaneous adipose tissue, regardless of percent
body fat, fat distribution, the presence or absence of type 2
diabetes, or adipocyte size; however, the factors regulating
this site-speciﬁc difference in RBP4 levels remain to be
elucidated. In fARKO mice, Rbp4 mRNA expression is
selectively increased in adipose tissue, but not in liver. We
are not aware of previous evidence directly relating AR
activity with RBP4 in mice, so we explored this interaction
in differentiated 3T3-L1 cells in which we showed direct
downregulation of RBP4 expression by nonaromatizable
androgen. Paradoxically, in humans, plasma RBP4 con-
centrations have been shown to be higher in males than
females (36), RBP4 expression is higher in visceral than
subcutaneous adipose tissue (37,38), and higher RBP4 ex-
pression has been associated with increased testosterone
levels and insulin resistance in women with polycystic
ovary syndrome (39); it is likely that regulation of RBP4
expression is complex and inﬂuenced not only by androgen
signaling but also by other confounding factors. However,
consistent with the metabolic phenotype of the fARKO
mouse, mice overexpressing RBP4 are hyperinsulinemic
and euglycemic and have no differences in NEFA or leptin
levels (20). The mechanism by which elevated adipose RBP4
levels induce insulin resistance is unclear; however, evidence
suggests that RBP4 may be released from adipocytes and act
locally to inhibit Tyr phosphorylation of IRS-1 (40), a molec-
ular defect implicated in human insulin resistance (41). In
fARKO mice, insulin-stimulated Tyr phosphorylation of IRS-1
at Tyr residue 612 was signiﬁcantly reduced. RBP4 may also
play an important role in lipid metabolism (42), and most
human studies that conﬁrm the association of RBP4 levels
with insulin resistance also observe signiﬁcant associations
with lipid levels, in particular with triglyceride, HDL choles-
terol, and LDL cholesterol (43–45). Elevated RBP4 therefore
provides a plausible mechanism for the metabolic abnormal-
ities observed in fARKO mice.
We conclude that AR signaling in adipose tissue plays
a critical role in glucose homeostasis independently of
adiposity. Disruption of this signaling can lead to the de-
velopment of insulin resistance, possibly via the dysregu-
lation of insulin-sensitizing adipokines. Manipulation of AR
activity at the level of the adipose tissue may therefore
provide a therapeutic target for the treatment of insulin
resistance associated with testosterone deﬁciency in males,
while avoiding potential adverse effects in other systems
such as prostate gland and hemostasis.
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